Stigmasterol and barasertib target cuproptosis-related prognostic model for the synergistic treatment of breast cancer.

Yongqin wang wang, Yuxiao Ma, Junyi Tan
2023 · doi:10.21203/rs.3.rs-3341565/v1
preprint OA: closed CC-BY-4.0
📄 Open PDF View at publisher

Abstract

Abstract Background Breast cancer (BRCA) has a high incidence and a poor prognosis. Cuproptosis is a crucial regulator of carcinogenesis and tumor progression. However, it has not been reported how cuproptosis in BRCA patients is treated using Chinese and Western medicines. Methods This study investigated how cuproptosis is used to diagnose and treat BRCA. A cuproptosis prognostic model was constructed using a bioinformatics approach. We used LASSO to establish a prognostic model associated with cuproptosis, and demonstrated the reliability of the model with survival analysis. Results CIBERSORT analysis showed that the prognostic model was associated with immune infiltration. An interesting finding from the CellMiner database analysis revealed a high correlation between the risk score and Barasertib. According to network pharmacology and molecular docking analysis, stigmasterol, an active ingredient of Curcuma longa L., may target the gene ADAM9 in the prognostic model. The combination of drugs confirmed that stigmasterol and barasertib had a significant synergistic effect on BRCA cells. Conclusion Our study provides a potential strategy for treating cuproptosis in combination with Chinese and Western medicines for BRCA.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (32)

Source provenance

crossref
last seen: 2026-06-27T06:33:05.206474+00:00
europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-4.0